Charleston Angel Partners Invests in Watershed Therapeutics

Charleston SC. - (April 19, 2023)

Charleston Angel Partners has invested in Bellevue-based start-up Watershed Therapeutics to drive expansion and growth. “Watershed Therapeutics offered CAP members not only the opportunity to participate in a very early stage investment but importantly the chance to be part of the solution for a medical condition impacting millions of people.  Throughout the due diligence period, we worked closely with Watershed’s CEO Topher Kinsella, and were impressed by both the technology and his developmental vision.  As this disruptive new medical device company moves forward in product development we feel comfortable that Topher and his team will effectively navigate the inevitable pivots required for success.”

“Charleston Angel Partners' unique structure as a member-driven organization allowed the group to react quickly and efficiently to the Watershed investment opportunity.  The due diligence committee consisted of both long-time CAP members and relatively new participants which provided a breadth of perspective and high energy.  Additionally, we were able to fully utilize the membership network and gather invaluable information and guidance from urologists throughout the Southeast.” said Brian Walton - CAPs Due Diligence team lead. 

Watershed Therapeutics frees millions of women from the fear of their next infection. Through comfortable, long-term bladder drug delivery, Watershed ensures that the bladder is protected from repeat infections of unwanted bacteria. Addressing a $7B market in recurrent UTIs, Watershed’s floating therapy is easily administered, lasts for months, and works in the background so that patients and their families don’t have to give the infection a second thought. 

Will Cruz, Executive Director, speaks fondly of Watershed, mentioning, “Watershed has an exceptional founder with deep domain experience, which made for a very easy decision to invest." 

Kinsella said, “Charleston Angel Partners were heads and shoulders above other investment groups in terms of their insight and interest. Not only did their diligence make the company better, but we brought on some of their advisors as consultants to the company. The trajectory of the company has improved - something only the best groups can claim for their portfolio companies.”